Roche Blockbuster Lucentis Gets FDA Nod For Broader Use
Roche Holding AG's blockbuster medicine Lucentis on Friday became the first pharmaceutical approved by the U.S. Food and Drug Administration for treatment of diabetic macular edema, an eye condition affecting more...To view the full article, register now.
Already a subscriber? Click here to view full article